- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
- Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
- Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
- Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
More ▼
Key statistics
As of last trade ACADIA Pharmaceuticals Inc (ACAD:NSQ) traded at 15.37, 4.91% above its 52-week low of 14.65, set on May 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.75 |
---|---|
High | 15.83 |
Low | 15.32 |
Bid | 15.36 |
Offer | 15.38 |
Previous close | 15.54 |
Average volume | 2.00m |
---|---|
Shares outstanding | 165.22m |
Free float | 164.42m |
P/E (TTM) | -- |
Market cap | 2.57bn USD |
EPS (TTM) | -0.0129 USD |
Data delayed at least 15 minutes, as of May 24 2024 16:37 BST.
More ▼